Intensity Therapeutics, INC Form 4 insider transactions

Thomas I H Dubin, a Director of Intensity Therapeutics, Inc., received 5,500 shares of common stock on July 16, 2026.

Daniel Donovan, a Director of Intensity Therapeutics, Inc., received 5,500 shares of common stock on July 16, 2026.

Mark A Goldberg, a Director of Intensity Therapeutics, Inc., received 5,500 shares of common stock on July 16, 2026.

Emer Leahy, a Director of Intensity Therapeutics, Inc., received 5,500 shares of common stock on July 16, 2026.

John M Wesolowski, Principal Accounting Officer of Intensity Therapeutics, Inc., received 11,000 shares of common stock on July 16, 2026.

Joseph Talamo, Chief Financial Officer of Intensity Therapeutics, Inc., received 34,000 shares of common stock on July 16, 2026.

Lewis H Bender, President and CEO and a Director of Intensity Therapeutics, Inc., received 78,000 shares of common stock on July 16, 2026.

John M. Wesolowski, an officer at Intensity Therapeutics, Inc., acquired shares through the company's Employee Stock Purchase Plan.

Joseph Talamo, Chief Financial Officer of Intensity Therapeutics, Inc., has acquired shares through the company's Employee Stock Purchase Plan.

CEO Lewis H. Bender received 37,749 fully vested shares at $6.11 as part of his 2025 bonus, lifting direct holdings to 118,549; amounts reflect a 1-for-25 reverse split effective 02/18/2026.

Intensity Therapeutics' Principal Accounting Officer, John M. Wesolowski, acquired 8,918 shares of common stock through the company's Employee Stock Purchase Plan.

Intensity Therapeutics CFO Joseph Talamo acquired 14,482 shares of common stock through the company's Employee Stock Purchase Plan at $0.262 per share.

Intensity Therapeutics' Principal Accounting Officer, John M. Wesolowski, acquired 69,745 shares of common stock at $0.261 per share through the company's 2024 Employee Stock Purchase Plan.

Intensity Therapeutics' Chief Financial Officer, Joseph Talamo, acquired 14,179 shares of common stock at $0.261 per share through the company's Employee Stock Purchase Plan.

Mark A. Goldberg, a director at Intensity Therapeutics, Inc., acquired options to purchase 50,000 shares of common stock.

John M. Wesolowski, Principal Accounting Officer of Intensity Therapeutics, Inc., reports the acquisition of stock options exercisable for 100,000 shares of common stock.

Director Thomas Dubin acquired options to purchase 50,000 shares of Intensity Therapeutics stock at $0.57 per share, vesting annually starting May 2, 2025.

Daniel Donovan, a director at Intensity Therapeutics, acquired options to purchase 50,000 shares of common stock at an exercise price of $0.57, vesting annually over four years starting May 2, 2025.

Director Emer Leahy of Intensity Therapeutics, Inc. reports the acquisition of stock options exercisable for 50,000 shares of common stock.

John M. Wesolowski, Principal Accounting Officer of Intensity Therapeutics, Inc., acquired stock options for 100,000 shares of common stock on May 2, 2025.

Lewis H. Bender, CEO of Intensity Therapeutics, Inc., was granted stock options to purchase 700,000 shares of common stock.

Joseph Talamo, CFO of Intensity Therapeutics, was granted stock options for 300,000 shares of common stock.

John M. Wesolowski, Principal Accounting Officer of Intensity Therapeutics, Inc., acquired stock options for 70,028 shares of common stock on October 21, 2024.

Joseph Talamo, CFO of Intensity Therapeutics, acquired stock options for 427,379 shares of common stock on October 21, 2024.

John M. Wesolowski, Principal Accounting Officer of Intensity Therapeutics, exercised stock options and corrected an error in a previous filing regarding beneficial ownership.

Director Thomas Dubin acquired 50,000 stock options in Intensity Therapeutics, Inc. on May 14, 2024.

John M. Wesolowski, Principal Accounting Officer and Controller of Intensity Therapeutics, Inc., acquired stock options for 25,000 shares on March 6, 2024.

Director Emer Leahy acquired stock options for 50,000 shares of Intensity Therapeutics common stock on March 6, 2024.

Mark A. Goldberg, a director of Intensity Therapeutics, Inc., acquired stock options for 50,000 shares on March 6, 2024.

Director Daniel Donovan acquired 50,000 stock options in Intensity Therapeutics, Inc. on March 6, 2024.